Effect of Transcranial Pulse Stimulation on ADHD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-01

Study Completion Date

2023-01-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is the first nationwide study using Transcranial Pulse Stimulation to evaluate its efficacy and safety on 30 young adolescents with ADHD. Six verum/ shamTPS sessions will be delivered to all subjects on a 1: 1 ratio, balanced by gender and age. Attention deficit, hyperactivity, impulsivity, and oppositional defiance will be the primary outcome. Secondary outcomes include ADHD severity, frequency of inattention, hyperactivity, impulsivity, executive function and neural connectivity changes via neuroimaging. Results emerging from this study will generate new knowledge to ascertain whether TPS can be used as a top-on treatment in ADHD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcutaneous Electrical Acupoint Stimulation for the Treatment of ADHD

NCT03917953

ADHD

COMPLETED NA

Brain Stimulation and Attention Control in Children With ADHD

NCT07182344

ADHD - Attention Deficit Disorder With Hyperactivity

ENROLLING_BY_INVITATION NA

Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT04704687

Attention Deficit Hyperactivity Disorder Transcranial Direct Current Stimulation

RECRUITING PHASE3

Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD

NCT07173439

ADHD - Attention Deficit Disorder With Hyperactivity ADHD - Combined Type ADHD

COMPLETED NA

The Efficacy of Cathodal tDCS in ADHD

NCT03955692

ADHD

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives of the study

1. To evaluate the efficacy and safety of TPS on young adolescents (12-17 years) with ADHD in Hong Kong.
2. To examine the association between TPS and ADHD core symptom severity, executive function, inattention, hyperactivity, impulsivity, and oppositional defiance.
3. To examine the brain functional connectivity changes immediately after the 2-week TPS treatment via neuroimaging.

Expected outcomes/Hypotheses:

1. Participants in the verum TPS group or the sham TPS group will have \<5% somatic discomfort in the 2-week TPS intervention and that TPS is a safe intervention on young adolescents with ADHD.
2. Participants in the verum TPS group will have 30% reduction in the Swanson, Nolan, and Pelham Rating Scale (SNAP IV score) (i.e., attention deficit, hyperactivity impulse and oppositional defiance) after 2-weeks TPS treatment compared with the sham TPS group and be maintained at the 1- month \& 3-month follow-up.
3. Participants in the verum TPS group will have 30% improvement in the ADHD symptoms and behaviour compared with the sham TPS group after 2-weeks TPS treatment and be maintained at the 1-month \& 3-month follow-up.
4. Participants in the verum TPS group will have 30% improvement in executive function after 2 weeks TPS treatment compared with the sham TPS group and be maintained at the 1-month \& 3-month follow-up.
5. Participants in the verum TPS group will have 30% improvement in both attention deficit \& reduction in hyperactivity, impulsivity after 2 weeks TPS treatment compared with the sham TPS group, and be maintained at the 1 month \& 3-month follow-up.
6. Participants in the verum TPS group will have more brain connectivity changes after 2-weeks TPS compared with the sham TPS group and be maintained at the 1 month \& 3-month follow-up.

Design: This is a two-armed, randomized, double-blind, sham-controlled trial.

Sample size:

To the best of our knowledge, there is no interventional study evaluating the efficacy of TPS on ADHD. Based on our previous open label pilot RCT 37 evaluating TPS on adults with Major Depressive Disorder that showed a large effect size (f = 0.47), we hypothesize a large effect of TPS in this study. We used G\*power version 3.1.9.4 to calculate the target sample size. With a statistical power of 95% and a statistical significance level at 0.05 to detect a large between-groups effect size (f) of 0.47 with 4 measurement time points, each group will require 15 subjects. A total sample of 30 is required in this trial. The attrition rate in our pilot MDD trial was 0%. We expect that the attrition rate in this ADHD trial would be \<5%. Subject dropping out the 2-week intervention period will be replaced by another enrolled subject in this pilot study.

Intervention (Transcranial Pulse Stimulation) Purpose of the intervention: The key tenets of the TPS intervention is neuromodulation, i.e., using ultrasound-based brain stimulation techniques to modulate the human brain in a focal and targeted manner. Intervention dose: Each participant should have the pre-treatment MRI scan performed in the University Research Facility in Behavioural and Systems Neuroscience, PolyU prior coming to the first intervention session. All participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time. Participants will be followed up immediately after post-stimulation in Week 2, and at 1-month and 3- month period after the intervention. The investigators believe that a 2-week TPS intervention is sufficient enough to test the effects of TPS on improving inattention and hyperactivity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a randomized, double-blinded, sham-controlled trial.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double-blind. Participants and interventionists will be blinded to the random allocation to either the verum TPS group or the sham TPS group.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transcranial Pulse Stimulation (TPS group)

Subjects in the TPS group will be given 6 verum TPS sessions (Pulse: 800 / session) across two weeks time, with 3 sessions per week.

Group Type EXPERIMENTAL

Transcranial Pulse Stimulation

Intervention Type DEVICE

A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .

Sham TPS Group

Subjects in the Sham TPS group will be given 6 sham TPS sessions across two weeks time, with 3 sessions per week.

Group Type SHAM_COMPARATOR

Transcranial Pulse Stimulation

Intervention Type DEVICE

A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial Pulse Stimulation

A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. have a confirmed diagnosis of ADHD according to the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) of the American Psychiatric Association;
2. ethic Chinese, aged 12-17, with no co-morbidity of other mental disorders (e.g., Intellectual Disability Disorder) and organic brain diseases that affected cognitive functions;
3. no severe systemic diseases including heart, liver, lung, and kidney diseases;
4. have an IQ \>80 by Stanford-Binet Intelligence Scales, 5th Edition (SB-5);
5. written consent by parents.

Exclusion Criteria

1. SNAP IV score \<1;
2. not taking ADHD medications in the past 2-4 weeks;
3. treated with TMS/rTMS/tDCS or electroconvulsive therapy in the past 12 months;
4. taking monoamine oxidase inhibitors in the past 14 days;
5. have a history of epilepsy, brain trauma, brain surgery/brain tumour, brain aneurysm or other concomitant unstable major medical conditions like haemophilia or other blood clotting disorders or thrombosis;
6. significant communicative impairments;
7. having metal implants in the brain treatment region /artificial cardiac pacemaker in-situ;
8. taking corticosteroid treatment within the last six weeks before the first TPS treatment;
9. have a history of micro-cavernomas.

Minimum Eligible Age

12 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No